Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes

Starting soon

Conditions studied: Type 1 Diabetes, Autoimmunity

In brief

Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes. The study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.

Key facts

Study ID
NCT07695727
Run by
IRCCS San Raffaele
People needed
84
Starts
2026-09-01
Expected to finish
2029-09-01
Last updated by the study team
2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.